Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 45,767 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 45,767 shares of Hims & Hers Health stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $16.33, for a total value of $747,375.11. Following the completion of the sale, the chief executive officer now directly owns 67,015 shares in the company, valued at approximately $1,094,354.95. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, September 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28.
• On Monday, August 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36.
• On Wednesday, July 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.75, for a total transaction of $3,919,426.00.

Hims & Hers Health Stock Up 5.0 %

Shares of HIMS stock opened at $17.27 on Wednesday. Hims & Hers Health, Inc. has a 12-month low of $5.65 and a 12-month high of $25.74. The company has a market capitalization of $3.71 billion, a PE ratio of -1,727.00 and a beta of 1.06. The firm has a 50 day moving average price of $17.11 and a two-hundred day moving average price of $17.13.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. During the same period last year, the firm posted ($0.03) EPS. The firm’s revenue for the quarter was up 51.8% compared to the same quarter last year. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC raised its stake in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares in the last quarter. Quest Partners LLC increased its holdings in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the period. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health in the second quarter valued at approximately $111,000. Amalgamated Bank boosted its stake in shares of Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the period. Finally, Daiwa Securities Group Inc. acquired a new stake in Hims & Hers Health during the second quarter worth approximately $142,000. Institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

HIMS has been the subject of a number of recent research reports. Bank of America reduced their price objective on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, September 13th. Piper Sandler reissued a “neutral” rating and set a $18.00 price target on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. TD Cowen upped their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Finally, Truist Financial raised their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.